1. Home
  2. XFOR

as 09-02-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Founded: 2014 Country:
United States
United States
Employees: 143 City: BOSTON
Market Cap: 84.3M IPO Year: N/A
Target Price: $34.17 AVG Volume (30 days): 10.6M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -14.76 EPS Growth: N/A
52 Week Low/High: $1.35 - $26.83 Next Earning Date: 08-08-2025
Revenue: $32,774,000 Revenue Growth: 5721.31%
Revenue Growth (this year): 1313.84% Revenue Growth (next year): -39.63%

XFOR Daily Stock ML Predictions

Share on Social Networks: